Anticancer Research May 1, 2007 vol. 27 no. 3B
H. PUHALLA, F. WRBA, D KANDIOLER,, M. LEHNERT, A. HUYNH, T. GRUENBERGER, D. TAMANDL, and M. FILIPITS
Abstract
Background:
To improve the prognosis of gallbladder cancer (GC) patients, a better understanding of the mechanisms of tumor development and progression is essential. The deregulation of cell cycle control is a critical step in the development of cancer. The purpose of this study was to investigate the expression of p21Wafl/Cip1, p57Kip2 and HER2/neu in an unselected GC patient population and to assess the association of these markers with p27Kip1 expression, p53 gene mutation status and clinical parameters of the patients.
Patients And Methods:
Formalin-fixed paraffin-embedded tissues from 55 operated GC patients were used to determine the expression of p21Wafl/Cip1, p57Kip2 and HER2/neu with immunohistochemistry. Results: Expression of p21Wafl/Cip1 was observed in 28%, of p57Kip2 in 19% and of HER2/neu in 13% of the patients. Absence of p57Kip2 expression was significantly associated with T3/T4 stage (p=0.01), positive lymph nodes (p=0.02) and advanced UICC stages (p=0.05). HER2/neu expression significantly correlated with advanced T stages (p=0.02). In the total patient population, p21Wafl/Cip1, p57Kip2 and HER2/neu had no impact on survival of the patients. Among patients with a mutated p53 gene, those without p21Wafl/Cip1 expression had a prolonged survival compared to patients with p21Wafl/Cip1 expression (p=0.004). Moreover, in p27Kip1-positive patients, those without p21Wafl/Cip1 expression had a longer survival than those with p21Wafl/Cip1 expression (p=0.003).
Conclusion:
In the subgroup of patients with a mutated p53 gene or in p27Kip1-positive patients, absence of p21Wafl/Cip1 expression may be associated with longer survival of GC patients. Therefore, further analyses of this protein in larger patient populations are warranted.
![]()
The Patricia A. Berardi Gallbladder Cancer Research Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
Federal Tax I.D.: EIN 86-0818253